EU GMP Chapter 7 has required a written contract between a contract giver and a contract acceptor since 31 January 2013. EU GMP Annex 21, in operation since 21 August 2022, extended that expectation to importers: written agreements must define who does what between the marketing authorisation holder, the importer, the site that certifies the batch, and the third-country manufacturer. For a Canadian Licensed Producer shipping dried flower to Germany, that third-country manufacturer is you.
A cannabis quality agreement is the document that makes those responsibilities enforceable. It sits beside the commercial supply agreement, not inside it, and it sets out who releases the batch, who tests what, who reports a deviation, and who decides on a recall. German importers holding a Manufacturing and Import Authorisation (MIA) will not have a Qualified Person (QP) certify your flower without one. Australian sponsors and Israeli distributors ask for the same thing under different names. Below: what goes in it, which nine clauses importers expect, and where Canadian LPs stall.
What a cannabis quality agreement covers (and what it doesn't)
A quality agreement, sometimes called a technical agreement or quality technical agreement (QTA), allocates GMP responsibilities between two regulated parties for a specific product. For dried cannabis flower moving from Canada to the EU, the two parties are the Canadian LP as manufacturer and the EU importer as MIA holder. The agreement covers manufacturing, testing, release, documentation, change control, deviations, complaints, recalls, storage, transport conditions, and audit rights. It does not cover price, volume, payment terms, or exclusivity. Those belong in the supply agreement, and mixing the two is the first mistake most LPs make.
The distinction matters because the two documents answer to different people. Commercial teams negotiate the supply agreement. The importer's QP and your Quality Assurance Person (QAP) own the quality agreement, and a regulator will ask to see it during an inspection. EU GMP Chapter 7 is explicit at section 7.15: the contract should describe clearly who undertakes each step, including testing, releasing materials, and quality controls. Section 7.17 adds that the contract giver must be permitted to audit the contract acceptor. Read those two clauses with Canadian eyes and the implication is direct. Your German customer has a regulatory obligation to audit you, and you have to agree to it in writing.
Why the Cannabis Regulations don't replace it
Under the Cannabis Regulations, every Canadian licence holder already operates under Good Production Practices and a named QAP approves each lot before release. That framework satisfies Health Canada. It does not satisfy an EU QP, because Canadian cannabis flower falls outside the GMP Mutual Recognition Agreement that covers conventional medicinal products between Canada and the EU. Health Canada does not issue GMP certificates to cannabis licence holders in the way it does for drug establishment licence holders, so EU authorities inspect Canadian cannabis sites directly and treat the flower as a third-country product that must be retested on import. Your QAP release is the start of the chain, not the end of it. A quality agreement is how the two systems are stitched together.
Why EU Annex 21 and QP batch release make it non-negotiable
Annex 21 was published on 16 February 2022 and came into operation six months later. The practical effect for a Canadian supplier is a change in sequence: German importers now send a quality agreement template with the first purchase order, not after the first delivery. The importer's QP now has a documented duty to confirm that a third-country batch was manufactured to standards recognised in the EU, to test it on arrival unless an MRA applies, to compare the import results against the supplier's certificate of analysis, and to investigate any out-of-trend result. None of that is possible without agreed specifications, agreed methods, and an agreed communication path for discrepancies.
The QP batch release step is where a missing or vague quality agreement produces a cost. If your COA reports total THC using one calculation and the German laboratory uses another, the QP sees a discrepancy and holds the batch. If your stability programme and the importer's shelf-life expectation were never aligned, the QP has no basis to assign an expiry date in the EU. A drying deviation you closed internally without telling the importer surfaces during the Product Quality Review, and the QP then questions every prior batch. Each of these is a paperwork failure, and each one shows up as a quarantined pallet in a Frankfurt warehouse.
Annex 21 also requires the PQR to assess whether the importer can keep relying on sampling performed in the third country. In plain terms: if your importer accepts samples you draw in Montreal, they have to justify that reliance every year, using data you supply. Write that data flow into the agreement or expect the importer to stop accepting your samples. Germany's 2026 enforcement against GMP washing has made importers far less willing to leave these points implicit.
The 9-clause cannabis quality agreement: what importers expect you to sign
Templates vary by importer, but the same nine clauses appear in nearly every agreement a Canadian LP receives from a German, Australian, or Israeli counterparty. The table below lists each clause, who typically owns it, and what the LP must be able to provide on day one.
| Clause | Who owns it | What the LP must provide |
|---|---|---|
| Product and specification | Both, signed by QP and QAP | Agreed spec sheet: cannabinoid ranges, water activity, microbial and contaminant limits, bud size |
| Manufacturing and GPP/GMP status | LP | Licence details, site master file, latest inspection outcome |
| Testing and release | Both | Which tests are done in Canada, by which ISO 17025 lab, and which are repeated in the EU |
| Documentation per batch | LP | Batch record summary, COA, packaging record, Health Canada export permit copy |
| Change control | LP notifies, importer approves | Written notice before changes to cultivar, process, packaging, or lab |
| Deviations and OOS results | LP reports, both investigate | Notification within an agreed number of business days, with root cause |
| Complaints and recall | Importer leads in market, LP supports | Named contact, 24-hour response, traceability to lot within hours |
| Storage, transport, and retention samples | Both | Temperature and humidity ranges, retention sample quantity and location |
| Audit rights and subcontractors | Importer audits LP | On-site or remote audit access, list of approved contract labs |
Two of these clauses generate most of the negotiation. The testing clause decides who pays for duplicate analysis and whose result wins when they disagree. The importer will usually insist that the EU result governs release in the EU, which is correct under Annex 21, but you should negotiate a documented investigation step before any batch is rejected on a single result. Our guide to batch rejection at import covers what that step looks like in practice.
The change control clause is the other pressure point. Importers want notice before you switch a contract laboratory or move a cultivar to a different room. LPs often see that as commercial interference. It isn't. The importer's QP has certified batches on the basis of a described process, and an unannounced change invalidates that basis. Agree on a tiered notification list: changes that need prior approval, changes that need notice, and changes that only need to appear in the annual quality review. That single table prevents most of the friction later.
Where Canadian LPs stall, and how to prepare before the first purchase order
Most Canadian LPs do not stall on the science. They stall on the fact that the Cannabis Regulations and EU GMP describe the same batch in different vocabularies. Health Canada wants a lot approved by a QAP against Canadian limits. The EU wants a batch certified by a QP against an agreed specification, with a Product Quality Review every year. Your documentation has to speak both languages, and the quality agreement is where you commit to the translation. Here is the preparation sequence that works.
- Write the specification before the importer does. Bring your own spec sheet to the table with cannabinoid ranges, water activity, microbial limits, foreign matter limits, and appearance criteria. An importer who receives a credible spec negotiates from it. An importer who receives nothing imposes theirs.
- Map your QAP release to their QP release. Document exactly which records the QAP reviews and which of those the importer will receive with every batch. Our article on QAP requirements sets out what the Canadian side already requires.
- Confirm your contract laboratory's scope. The agreement will name the lab and the methods. If the lab's ISO/IEC 17025 accreditation scope doesn't include every method listed, the importer will find out during the first audit.
- Set deviation and recall timelines you can meet. Importers often propose 24-hour notification for critical deviations and 48 hours for others. Agree only to what your quality system can deliver at 2 a.m. on a Saturday in Montreal when the importer is at 8 a.m. in Berlin. Then link the clause to your existing recall procedure rather than writing a new one.
- Prepare for the audit before you sign. Section 7.17 gives the importer the right to audit you. Run a mock audit against EU GMP Part I chapters 4, 6, 7, and 8 and fix the gaps first. The first real audit then confirms what you already know.
If the importer's QP won't sign a quality agreement before the first commercial batch, don't ship the first commercial batch. A QP who skips the agreement will also skip the investigation step when a result comes back out of trend, and you will lose the batch with no recourse.
AlphaLeaf is a Health Canada Licensed Producer in Montreal growing indoor, hand-trimmed cannabis flower with ISO/IEC 17025-tested batch data and lot-level traceability from room to shipping carton. We hold export authorisation under the Cannabis Act and maintain the specification, deviation, and change-control documentation that EU importers need to certify a Canadian batch under Annex 21. If your quality team is drafting or reviewing a quality agreement with a Canadian supplier, contact AlphaLeaf to request our specification template and batch documentation package. The agreement is the easy part. Meeting it every batch is the work.
Frequently Asked Questions
What is a cannabis quality agreement?
A cannabis quality agreement (also called a technical agreement) is a written contract between a manufacturer, such as a Canadian Licensed Producer, and a regulated buyer, such as an EU importer, that allocates GMP responsibilities for a specific product. It covers specifications, testing, batch release, documentation, change control, deviations, complaints, recalls, storage, transport, and audit rights. It is separate from the commercial supply agreement.
Is a quality agreement legally required to export cannabis from Canada to Germany?
Health Canada does not require one to issue an export permit. The requirement comes from the EU side: EU GMP Chapter 7 requires a written contract for outsourced activities, and Annex 21 requires written agreements defining responsibilities between the importer, the QP certification site, and the third-country manufacturer. In practice, a German MIA holder will not certify a Canadian batch without a signed quality agreement.
What is the difference between a quality agreement and a supply agreement?
The supply agreement covers commercial terms: price, volume, delivery schedule, payment, and exclusivity. The quality agreement covers regulatory responsibilities: who tests, who releases, who reports deviations, and who leads a recall. Quality teams and the importer's Qualified Person own the quality agreement. Commercial teams own the supply agreement. Regulators inspect the quality agreement, not the supply agreement.
Who signs a cannabis quality agreement on each side?
On the Canadian side, the Licensed Producer's Quality Assurance Person or head of quality signs. On the EU side, the importer's Qualified Person or head of quality signs. Some importers also require a senior officer's signature. The signatories should be the people who will execute the responsibilities, rather than the commercial leads alone.
Does an EU importer have to retest Canadian cannabis flower on arrival?
Yes. Under Annex 21, imported medicinal products must be tested on importation unless they come from a country covered by a Mutual Recognition Agreement or similar arrangement for that product. Canadian cannabis flower is not covered by the Canada-EU GMP MRA, so the importer's QP must arrange EU testing and compare the results with the Canadian certificate of analysis before certifying the batch.
How often should a cannabis quality agreement be reviewed?
Most agreements set a formal review at least once a year, aligned with the importer's Product Quality Review under EU GMP Chapter 1, and an immediate review whenever a significant change occurs, such as a new contract laboratory, a new cultivar, a change in packaging, or a regulatory change in either country. The agreement should state its own review cycle.
